| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
|
N Engl J Med
|
2015
|
12.74
|
|
2
|
Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
|
N Engl J Med
|
2013
|
10.74
|
|
3
|
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
|
J Clin Oncol
|
2009
|
8.16
|
|
4
|
Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
|
JAMA
|
2011
|
7.61
|
|
5
|
Marital status and survival in patients with cancer.
|
J Clin Oncol
|
2013
|
5.82
|
|
6
|
Cost implications of the rapid adoption of newer technologies for treating prostate cancer.
|
J Clin Oncol
|
2011
|
4.60
|
|
7
|
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.
|
Lancet Oncol
|
2013
|
3.19
|
|
8
|
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
|
N Engl J Med
|
2015
|
3.00
|
|
9
|
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.
|
Lancet Oncol
|
2012
|
2.84
|
|
10
|
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.
|
Cancer Discov
|
2014
|
2.79
|
|
11
|
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study.
|
Lancet Oncol
|
2012
|
2.44
|
|
12
|
NCCN clinical practice guidelines in oncology: kidney cancer.
|
J Natl Compr Canc Netw
|
2009
|
2.40
|
|
13
|
Prospective evaluation of analgesic use and risk of renal cell cancer.
|
Arch Intern Med
|
2011
|
2.34
|
|
14
|
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
|
Clin Cancer Res
|
2011
|
2.27
|
|
15
|
Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR.
|
Am J Surg Pathol
|
2006
|
2.23
|
|
16
|
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
|
Lancet Oncol
|
2009
|
2.23
|
|
17
|
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
|
J Clin Oncol
|
2010
|
2.18
|
|
18
|
Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
|
BJU Int
|
2011
|
2.07
|
|
19
|
A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy.
|
Cancer
|
2014
|
2.05
|
|
20
|
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone.
|
Urology
|
2013
|
2.04
|
|
21
|
Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
|
J Clin Oncol
|
2011
|
2.02
|
|
22
|
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis.
|
J Clin Oncol
|
2012
|
2.00
|
|
23
|
NCCN clinical practice guidelines in oncology: testicular cancer.
|
J Natl Compr Canc Netw
|
2009
|
1.86
|
|
24
|
Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample.
|
Eur Urol
|
2012
|
1.86
|
|
25
|
Utilization and expense of adjuvant cancer therapies following radical prostatectomy.
|
Cancer
|
2011
|
1.85
|
|
26
|
Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy.
|
Urology
|
2010
|
1.83
|
|
27
|
Factors associated with the adoption of minimally invasive radical prostatectomy in the United States.
|
J Urol
|
2012
|
1.78
|
|
28
|
Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era.
|
J Clin Oncol
|
2014
|
1.74
|
|
29
|
Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007.
|
BJU Int
|
2013
|
1.73
|
|
30
|
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
|
Urology
|
2010
|
1.68
|
|
31
|
The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma.
|
Haematologica
|
2006
|
1.67
|
|
32
|
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
|
Eur Urol
|
2012
|
1.64
|
|
33
|
Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria.
|
Cancer
|
2013
|
1.53
|
|
34
|
Sunitinib rechallenge in metastatic renal cell carcinoma patients.
|
Cancer
|
2010
|
1.52
|
|
35
|
Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.
|
Cancer
|
2010
|
1.52
|
|
36
|
Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients.
|
Clin Cancer Res
|
2006
|
1.45
|
|
37
|
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.44
|
|
38
|
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
|
Eur Urol
|
2011
|
1.43
|
|
39
|
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib.
|
N Engl J Med
|
2014
|
1.43
|
|
40
|
Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period.
|
Cancer
|
2014
|
1.41
|
|
41
|
Pazopanib: Clinical development of a potent anti-angiogenic drug.
|
Crit Rev Oncol Hematol
|
2010
|
1.36
|
|
42
|
Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials.
|
J Urol
|
2010
|
1.29
|
|
43
|
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure.
|
Eur J Cancer
|
2011
|
1.26
|
|
44
|
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
|
J Clin Oncol
|
2012
|
1.24
|
|
45
|
Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia.
|
Mayo Clin Proc
|
2005
|
1.22
|
|
46
|
Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma.
|
J Urol
|
2010
|
1.22
|
|
47
|
Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
|
J Urol
|
2007
|
1.13
|
|
48
|
Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.
|
Cancer
|
2013
|
1.12
|
|
49
|
Testicular cancer.
|
J Natl Compr Canc Netw
|
2012
|
1.11
|
|
50
|
Patterns of care for radical prostatectomy in the United States from 2003 to 2005.
|
J Urol
|
2008
|
1.08
|
|
51
|
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
|
Cancer
|
2012
|
1.07
|
|
52
|
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome.
|
Eur J Cancer
|
2012
|
1.07
|
|
53
|
Kidney cancer.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
54
|
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.
|
Hypertension
|
2010
|
1.05
|
|
55
|
Risk of bilateral renal cell cancer.
|
J Clin Oncol
|
2009
|
1.04
|
|
56
|
The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients.
|
Curr Oncol Rep
|
2012
|
1.03
|
|
57
|
Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
|
Cancer J
|
2013
|
1.00
|
|
58
|
Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.00
|
|
59
|
Non-clear cell renal cancer: features and medical management.
|
J Natl Compr Canc Netw
|
2009
|
1.00
|
|
60
|
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?
|
Eur Urol
|
2011
|
1.00
|
|
61
|
Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy.
|
Prostate
|
2011
|
1.00
|
|
62
|
Treatment selection for patients with metastatic renal cell carcinoma.
|
Cancer
|
2009
|
0.99
|
|
63
|
Elicitation of health state utilities in metastatic renal cell carcinoma.
|
Curr Med Res Opin
|
2010
|
0.99
|
|
64
|
Kidney cancer, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.98
|
|
65
|
Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.
|
Cancer
|
2014
|
0.98
|
|
66
|
10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.
|
Oncologist
|
2014
|
0.97
|
|
67
|
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
|
Cancer
|
2008
|
0.97
|
|
68
|
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.
|
Target Oncol
|
2013
|
0.95
|
|
69
|
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
|
Cancer Med
|
2014
|
0.95
|
|
70
|
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
|
J Natl Compr Canc Netw
|
2011
|
0.94
|
|
71
|
The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
|
Breast J
|
2007
|
0.94
|
|
72
|
Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.
|
Trends Cardiovasc Med
|
2013
|
0.94
|
|
73
|
Differential expression of caveolin-1 in renal neoplasms.
|
Cancer
|
2007
|
0.93
|
|
74
|
ABO blood group and risk of renal cell cancer.
|
Cancer Epidemiol
|
2012
|
0.93
|
|
75
|
Optimizing recent advances in metastatic renal cell carcinoma.
|
Curr Oncol Rep
|
2009
|
0.92
|
|
76
|
Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.
|
Crit Rev Oncol Hematol
|
2011
|
0.92
|
|
77
|
Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
|
Future Oncol
|
2008
|
0.91
|
|
78
|
Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients.
|
Acta Oncol
|
2013
|
0.90
|
|
79
|
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
|
Hematol Oncol Clin North Am
|
2011
|
0.90
|
|
80
|
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma.
|
Clin Cancer Res
|
2014
|
0.90
|
|
81
|
Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system.
|
BMJ Open
|
2014
|
0.89
|
|
82
|
Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis.
|
J Natl Cancer Inst
|
2012
|
0.89
|
|
83
|
Metabolic complications with the use of mTOR inhibitors for cancer therapy.
|
Cancer Treat Rev
|
2013
|
0.89
|
|
84
|
Updates on novel therapies for metastatic renal cell carcinoma.
|
Ther Adv Med Oncol
|
2010
|
0.89
|
|
85
|
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.
|
Crit Rev Oncol Hematol
|
2013
|
0.89
|
|
86
|
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
|
Cancer J
|
2014
|
0.88
|
|
87
|
Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men.
|
Urology
|
2010
|
0.87
|
|
88
|
Haematologic toxicities associated with the addition of bevacizumab in cancer patients.
|
Eur J Cancer
|
2011
|
0.87
|
|
89
|
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
|
BJU Int
|
2014
|
0.86
|
|
90
|
The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.
|
Cancer
|
2011
|
0.86
|
|
91
|
Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts.
|
Cancer
|
2011
|
0.86
|
|
92
|
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies.
|
J Natl Compr Canc Netw
|
2014
|
0.86
|
|
93
|
Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.
|
Aging Male
|
2011
|
0.86
|
|
94
|
Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke.
|
BJU Int
|
2010
|
0.86
|
|
95
|
Testicular Cancer, Version 2.2015.
|
J Natl Compr Canc Netw
|
2015
|
0.86
|
|
96
|
Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design.
|
Clin Genitourin Cancer
|
2013
|
0.85
|
|
97
|
Use of surveillance imaging following treatment of small renal masses.
|
J Urol
|
2013
|
0.85
|
|
98
|
Recent advances in immunotherapy for the treatment of prostate cancer.
|
Expert Opin Biol Ther
|
2011
|
0.85
|
|
99
|
Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid.
|
Expert Opin Drug Saf
|
2011
|
0.83
|
|
100
|
Everolimus- and temsirolimus-associated enteritis: report of three cases.
|
J Clin Oncol
|
2011
|
0.83
|
|
101
|
Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.
|
Curr Med Res Opin
|
2009
|
0.83
|
|
102
|
Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
|
Curr Treat Options Cardiovasc Med
|
2014
|
0.83
|
|
103
|
Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).
|
BJU Int
|
2014
|
0.82
|
|
104
|
RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
|
AJR Am J Roentgenol
|
2015
|
0.81
|
|
105
|
Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.
|
Eur J Cancer
|
2011
|
0.81
|
|
106
|
Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
|
Curr Oncol Rep
|
2006
|
0.80
|
|
107
|
Rationale for and review of neoadjuvant therapy prior to radical prostatectomy for patients with high-risk prostate cancer.
|
Drugs
|
2013
|
0.80
|
|
108
|
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.
|
J Clin Oncol
|
2012
|
0.80
|
|
109
|
Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
|
Urol Oncol
|
2010
|
0.80
|
|
110
|
Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality.
|
J Urol
|
2012
|
0.80
|
|
111
|
Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis.
|
J Urol
|
2009
|
0.80
|
|
112
|
New therapies for castrate-resistant prostate cancer.
|
Expert Opin Pharmacother
|
2011
|
0.80
|
|
113
|
Recent advances in the systemic treatment of metastatic papillary renal cancer.
|
Expert Rev Anticancer Ther
|
2009
|
0.79
|
|
114
|
Treatment of Advanced Renal-Cell Carcinoma.
|
N Engl J Med
|
2016
|
0.79
|
|
115
|
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
|
Clin Genitourin Cancer
|
2013
|
0.79
|
|
116
|
Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.
|
Target Oncol
|
2013
|
0.79
|
|
117
|
The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions.
|
J Natl Compr Canc Netw
|
2015
|
0.79
|
|
118
|
Impact of body composition on clinical outcomes in metastatic renal cell cancer.
|
Oncologist
|
2011
|
0.78
|
|
119
|
Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence.
|
Cancer
|
2010
|
0.78
|
|
120
|
Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma.
|
J Clin Oncol
|
2010
|
0.77
|
|
121
|
Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis.
|
Am J Clin Oncol
|
2016
|
0.77
|
|
122
|
Genomic investigation of etiologic heterogeneity: methodologic challenges.
|
BMC Med Res Methodol
|
2014
|
0.76
|
|
123
|
Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer.
|
Eur Urol
|
2009
|
0.76
|
|
124
|
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.
|
Cancer Cell
|
2016
|
0.76
|
|
125
|
Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer.
|
Hematol Oncol Clin North Am
|
2013
|
0.75
|
|
126
|
¹¹C-methionine positron-emission tomography and computed tomography (PET-CT) in evaluating metastatic transitional cell carcinoma response to sunitinib therapy.
|
BJU Int
|
2010
|
0.75
|
|
127
|
Sunitinib in renal-cell carcinoma: expanded indications.
|
Lancet Oncol
|
2009
|
0.75
|
|
128
|
RET protein expression in papillary renal cell carcinoma.
|
Urol Oncol
|
2011
|
0.75
|
|
129
|
The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy.
|
Nat Clin Pract Oncol
|
2008
|
0.75
|
|
130
|
Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.
|
Brachytherapy
|
2013
|
0.75
|
|
131
|
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2017
|
0.75
|